EurekaMag.com logo
+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Immune response to inactivated influenza virus vaccine: antibody reactivity with epidemic influenza B viruses of two highly distinct evolutionary lineages



Immune response to inactivated influenza virus vaccine: antibody reactivity with epidemic influenza B viruses of two highly distinct evolutionary lineages



Vaccine 10(9): 631-636



Vaccination of adults (healthy female employees potentially capable of transmitting influenza to high-risk persons; n = 104) in autumn 1990 with a trivalent influenza virus vaccine containing B/Yamagata/16/88 induced a low antibody response to B/Finland/150/90, a recent variant of B/Victoria/2/87-like viruses, as compared with the antibody response to B/Finland/172/91, a current variant in the lineage of B/Yamagata/16/88-like viruses. Up to the end of the epidemic season, the antibody status declined but was still significantly better than before the vaccination. The results suggest that the vaccine strain was appropriate for the outbreak of 1990 to 1991 in Finland, but may provide unsatisfactory protection against B/Victoria/2/87-like viruses. Evidence is given that use of Madin-Darby canine kidney (MDCK)-grown virus as an antigen in the haemagglutination inhibition test (HI) may provide more reliable information about the protective antibodies than use of untreated or ether-treated egg-grown viruses. Significantly higher postvaccination and postepidemic antibody titres were recorded among subjects who exhibited the antibody before vaccination than among seronegative subjects. A significantly higher response rate among initially seronegative people than among seropositive people was recorded for antibody to B/Finland/150/90, but no clear evidence was obtained that the pre-existing antibody could have had a negative effect on the antibody production.

(PDF emailed within 0-6 h: $19.90)

Accession: 040354510

Download citation: RISBibTeXText

PMID: 1502842

DOI: 10.1016/0264-410x(92)90446-q



Related references

Serological responses in volunteers to inactivated trivalent subunit influenza vaccine: antibody reactivity with epidemic influenza A and B strains and evidence of a rapid immune response. Journal of Medical Virology 33(2): 133-137, 1991

Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 26(29-30): 3626-3633, 2008

Antigenic response to influenza virus in man. II. Neutralizing antibody response to inactivated monovalent B vaccine, with observations on vaccine efficacy during a subsequent type B epidemic. American Journal of Epidemiology 90(4): 336-343, 1969

Antigenic response to influenza virus in man. I. Neutralizing antibody response to inactivated monovalent A2 vaccine as related to prior influenza exposure. American Journal of Epidemiology 90(4): 327-335, 1969

Influenza virus antibody response in nasal secretion and sputum following respiratory administration of inactivated influenza vaccine. Abstracts of the Annual Meeting of the American Society for Microbiology 77: 112, 1977

Inactivated influenza vaccine (H1N1, H3N2, H3N1) - antibody response and protective effect in the influenza epidemic H1N1 in 1979. Ceskoslovenska Epidemiologie, Mikrobiologie, Imunologie 30(5): 287-293, 1981

Potency of an inactivated influenza vaccine prepared from a non-pathogenic H5N1 virus against a challenge with antigenically drifted highly pathogenic avian influenza viruses in chickens. Veterinary Microbiology 164(1-2): 39-45, 2013

Influenza vaccination in elderly residents in nursing homes: immune response to trivalent and monovalent inactivated influenza virus vaccine in the season 1986-87. European Journal of Epidemiology 5(2): 214-218, 1989

Influenza B virus evolution: co-circulating lineages and comparison of evolutionary pattern with those of influenza A and C viruses. Virology 163(1): 112-122, 1988

Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 25(18): 3554-3560, 2007

Immune response in domestic ducks following intradermal delivery of inactivated vaccine against H5N1 highly pathogenic avian influenza virus adjuvanted with oligodeoxynucleotides containing CpG motifs. Poultry Science 94(8): 1836-1842, 2015

Influenza viruses and cross-reactivity in healthy adults Humoral and cellular immunity induced by seasonal 27/28 influenza vaccination against vaccine antigens and 29 AH1N1 pandemic influenza virus. 2012

Toxicities of influenza vaccine: peripheral leukocytic response to live and inactivated influenza viruses in mice. Japanese Journal of Medical Science & Biology 28(1): 37-52, 1975

Initiation and regulation of immune responses to immunization with whole inactivated vaccines prepared from two genetically and antigenically distinct lineages of Egyptian influenza A virus subtype H5N1. Archives of Virology 161(10): 2797-2806, 2016

Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus. Vaccine 30(9): 1617-1623, 2012